Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b.
Serum antibody response to a conjugated Haemophilus influenzae type b polyribosylribitol phosphate-diphtheria toxoid vaccine was assessed in nonvaccinated children aged 1 1/2 to 5 years receiving chemotherapy for solid tumors. Responses occurred in 21 (42%) of 50 children after first vaccination, and in 10 (45%) of 22 revaccinated children.
Shenep
J L
JL
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105-2794.
Feldman
S
S
Gigliotti
F
F
Roberson
P K
PK
Marina
N
N
Foreschle
J E
JE
Fullen
G H
GH
Lott
L
L
Brodkey
T O
TO
D000914:Antibodies, Viral / Q000097:blood*; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology*
D000914:Antibodies, Viral; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; D018074:Vaccines, Conjugate